Advagene Biopharma Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Selling, General & Admin	20.16	20.55	20.12	19.77	21.75	20.46
Research & Development	53.08	50.27	73.22	100.04	72.68	55.33
Operating Expenses	73.24	70.82	93.34	119.81	94.43	75.79
Operating Income	-73.24	-70.82	-93.34	-119.81	-94.43	-75.79
Interest Expense	-0.21	-0.15	-0.04	-0.08	-0.12	-0.11
Interest & Investment Income	2.41	1.7	1.02	1.31	1.53	1.7
Currency Exchange Gain (Loss)	-0.2	-0.2	0.25	0.2	0.12	-0
Other Non Operating Income (Expenses)	0.13	0.06	-	-	0.16	3.9
EBT Excluding Unusual Items	-71.1	-69.42	-92.11	-118.38	-92.74	-70.31
Gain (Loss) on Sale of Investments	-	-	-	-	0.05	0.15
Pretax Income	-71.1	-69.42	-92.11	-118.38	-92.69	-70.16
Net Income	-71.1	-69.42	-92.11	-118.38	-92.69	-70.16
Net Income to Common	-71.1	-69.42	-92.11	-118.38	-92.69	-70.16
Shares Outstanding (Basic)	58	55	50	49	49	44
Shares Outstanding (Diluted)	58	55	50	49	49	44
Shares Change (YoY)	10.02%	8.47%	2.14%	1.23%	9.95%	0.28%
EPS (Basic)	-1.23	-1.27	-1.83	-2.40	-1.90	-1.58
EPS (Diluted)	-1.23	-1.27	-1.83	-2.40	-1.90	-1.58
Free Cash Flow	-77.03	-71.12	-77.7	-109.56	-67.7	-31.51
Free Cash Flow Per Share	-1.34	-1.30	-1.54	-2.22	-1.39	-0.71
EBITDA	-72.95	-70.52	-89.32	-115.25	-89.24	-70.41
D&A For EBITDA	0.29	0.31	4.02	4.56	5.19	5.39
EBIT	-73.24	-70.82	-93.34	-119.81	-94.43	-75.79

Source: S&P Global Market Intelligence. Standard template. Financial Sources.